Hoth Therapeutics, Inc. (HOTH)
| Market Cap | 13.96M +8.4% |
| Revenue (ttm) | n/a |
| Net Income | -12.47M |
| EPS | -0.90 |
| Shares Out | 19.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 983,850 |
| Open | 0.7169 |
| Previous Close | 0.7432 |
| Day's Range | 0.6966 - 0.7455 |
| 52-Week Range | 0.4894 - 2.1150 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+584.93%) |
| Earnings Date | May 11, 2026 |
About HOTH
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or ot... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price target is $5.0.
News
Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug
The HT-VA study demonstrated that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) significantly reduces fat production and enhances fat metabolism at the genetic level, positioning it as a un...
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 14, 2026 /PRNewswire/...
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann...
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ann...
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA...
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast Cells NEW YORK, March 31, 2026 /PRNewswire/ -- H...
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computa...
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations . Safety and tolerability findings included: No serious a...
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female mice Treatment preserved hepatic autophagy and maintained norma...
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceu...
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Thera...
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wego...
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study
Hoth Therapeutics Inc. (NASDAQ: HOTH) on Tuesday revealed preclinical data from its study on glial cell-derived neurotrophic factor (GDNF) for obesity and metabolic-associated steatotic liver disease ...
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant...
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTC...
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ --...
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and opera...
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the ...
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipel...
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today a...
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has ...
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Hoth Ther...
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Plan...
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural ...
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumors NEW YORK , Oct. 7, 2...